Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZOMIG

« Back to Dashboard
Zomig is a drug marketed by Astrazeneca and IPR and is included in three NDAs. It is available from five suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ZOMIG is zolmitriptan. There are twenty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.

Summary for Tradename: ZOMIG

Suppliers / Packagers: see list15

Clinical Trials for: ZOMIG

Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Status: Completed Condition: Migraine

Zomig - Treatment of Acute Migraine Headache in Adolescents
Status: Completed Condition: Migraine Headache

ZAP, US. Zomig for Appropriate for Primary Care
Status: Completed Condition: Migraine

Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
Status: Completed Condition: Migraine

Efficacy and Tolerability of Zolmitriptan Nasal Spray
Status: Completed Condition: Migraine

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
Status: Recruiting Condition: Migraine

Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine
Status: Completed Condition: Acute Migraine; Migraine Headache; Headache Disorders

Effects of Zolmitriptan on Sensory Transmission After Spinal Cord Injury
Status: Completed Condition: Spinal Cord Injuries; Muscle Spasticity

Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Status: Completed Condition: Migraine

Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Status: Completed Condition: Migraine Disorders

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
SPRAY;NASAL021450-003Sep 16, 2013RXNo7,220,767*PED<disabled>Y<disabled>
TABLET;ORAL020768-001Nov 25, 1997RXNo<disabled><disabled>
SPRAY;NASAL021450-004Sep 30, 2003RXYes7,220,767*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZOMIG

Drugname Dosage Strength RLD Submissiondate
zolmitriptanNasal Spray5 mg/sprayZomig11/14/2013
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn